Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Inc Ordinary Shares DFTX
News
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
Psychedelic stocks surge after Trump supports using drugs like LSD for mental health
United States